News Room

SOURCE: NeuroInvestment

March 03, 2008 13:21 ET

Bipolar Disorder Therapeutics Reviewed by NeuroInvestment

CARDIFF, CA--(Marketwire - March 3, 2008) - NI Research has released the March issue of NeuroInvestment. The issue features a review of Bipolar Disorder, a disorder whose reputation for artistic creativity and expansiveness belies the havoc and destruction that it can wreak. Bipolar is the neglected stepchild of the neuropharmaceutical world; in spite of its large market scale, and the flaws in the current (albeit often cheap) drugs currently used in its treatment, bipolar almost invariably awaits molecular 'hand-me-downs' from antipsychotic and anticonvulsant label-expansion programs.

The contents of the March NeuroInvestment include: 

1) Bipolar programs covered in the review include those from Lundbeck,
   Affectis, Noven, and Repligen.
2) A review of Intra-Cellular Therapies, with drugs in development for
   schizophrenia, insomnia, and female sexual dysfunction.
3) Analysis regarding POC trials from Allon Therapeutics, Prana
   Biotechnology, and Neuro-Hitech.
4) Commentary on Cephalon's credibility gap

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year corporate subscription is $1600, email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery outside North America. A three-month trial subscription is US$600.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, and the Private CNS Company Review since 2003. In 2007 NI Research launched an annual compendium of all neuro-oriented R&D programs organized by disorder, CNS Disorders/Therapeutics, as well as an annual review of the Alzheimer's therapeutics area, Alzheimer's 2008. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies.

Contact Information

News Room